Drug Profile
Ciclosporin A ophthalmic - Laboratorios Sophia/Novartis
Alternative Names: Cyclosporine opthalmic solution; Novartis; ST-603; ZyclorinLatest Information Update: 24 Dec 2021
Price :
$50
*
At a glance
- Originator Laboratorios Sophia
- Developer Novartis
- Class Anti-inflammatories; Antineoplastics; Antipsoriatics; Antirheumatics; Ciclosporins; Eye disorder therapies; Heart failure therapies; Neuroprotectants
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Dry eyes
Most Recent Events
- 09 Apr 2019 Novartis completed the spin-off of Alcon eye care devices business
- 30 Mar 2013 Discontinued - Phase-III for Dry eyes in USA (Topical)
- 30 Mar 2012 No development reported - Phase-III for Dry eyes in USA (Topical)